<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;L01E&quot;,&quot;href&quot;:&quot;atc/L01E.md&quot;},{&quot;label&quot;:&quot;inavolisib&quot;}]"></div>

# inavolisib

- **generic name:** inavolisib
- **ATC codes:** `L01EM06`
- **DrugBank:** [DB15275](https://go.drugbank.com/drugs/DB15275) · **PubChem:** not captured
- **molar mass:** 407.378 g/mol (C18H19F2N5O4) — DrugBank
- **groups:** approved, investigational

## About

Inavolisib is a PI3K inhibitor anticancer drug used to treat breast cancer. It is an approved medicine, with one product authorised in the European Union, and remains investigational for other uses.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q76855355](https://www.wikidata.org/wiki/Q76855355) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## popPK records

_not available_

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">Rejected</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Iannuzzi_2025_cell_viability](drugs/drug_inavolisib/pd_Iannuzzi_2025_cell_viability.md) | cell viability ← Inavolisib · inhibition effect | — | Iannuzzi CA et al., Caprine herpes virus-1 reduces cell via…, Frontiers in oncology (2025) | [10.3389/fonc.2025.1676296](https://doi.org/10.3389/fonc.2025.1676296) |

## ADME sites

Tissue mappings from DrugBank molecular actors and paper-derived PGx genes. Compare drugs in [Sites & interactions](sites?drugs=inavolisib).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | `ABCG2` substrate | DrugBank actor |
| distribution | blood-brain barrier | `ABCG2` substrate | DrugBank actor |
| distribution | mammary gland | `ABCG2` substrate | DrugBank actor |
| distribution | testis | `ABCG2` substrate | DrugBank actor |
| metabolism | liver | `CYP2B6` inducer, `CYP3A4` inducer/inhibitor/substrate | DrugBank actor |
| metabolism | small intestine | `CYP3A4` inducer/inhibitor/substrate | DrugBank actor |
| excretion | bile duct | <sub>named in DrugBank's ADME text</sub> | DrugBank ADME |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | DrugBank ADME |
| excretion | liver | `ABCG2` substrate | DrugBank actor |

<sub>Actors without a tissue in the table: ABCB5 (substrate), PIK3CA (degradation), PIK3CG (inhibitor).</sub>

<details class="legend">
<summary>Status and cross-check definitions</summary>
<table><thead><tr><th>Badge</th><th>Definition</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">Curated (human-checked)</span></td><td>Authored or checked by a person against the paper.</td></tr><tr><td><span class="pk-badge pk-badge--green">Reproduces paper</span></td><td>The model built from the extracted parameters reproduces the paper's reported reference values; not human-verified.</td></tr><tr><td><span class="pk-badge pk-badge--green">Reproduces with caveats</span></td><td>Reproduces the paper's reference values, but an advisory check is open (for example, covariate scenarios not evaluated).</td></tr><tr><td><span class="pk-badge pk-badge--neutral">Not simulated</span></td><td>Extracted and checked against closed-form rules, but no simulation has compared it with the paper yet. Not a verdict.</td></tr><tr><td><span class="pk-badge pk-badge--orange">Needs review</span></td><td>Incomplete, inconsistent or implausible extraction, or a failed replication; the values are unverified.</td></tr><tr><td><span class="pk-badge pk-badge--red">Rejected</span></td><td>Not accepted; the values are shown for inspection only.</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>Reviewed before the paper was last screened; a new review is pending, so the status comes from the automatic checks.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>All responding readers agree on all compared fields; fractions indicate agreeing/total readers.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>At least one non-structural discrepancy or incomplete reader agreement.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>At least one structural-parameter discrepancy; primary extraction retained pending review.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>Non-human or in-vitro evidence; parameters and simulations describe the stated experimental system.</td></tr></tbody></table>
<p><small><b>Status</b> reports validation and review outcomes; <b>cross-check</b> reports agreement between independent extractions. Agreement does not establish plausibility, model validity, or clinical applicability.</small></p>
</details>

<details class="pk-pipeline"><summary>Pipeline details</summary>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-07 01:42 | 0:18 | 0/0/0 | 0/1/0 | 0/0/0 | 15,576/1,831 | openai / gpt-6-luna | 1 | 0/1 | 1/0 | 0 |

## Coverage

- **PubMed hits:** 1 matched, 1 returned
- **screened:** 0  ·  **relevant:** 0
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Iannuzzi_2025 | irrelevant | 0 | 0 | This is an in-vitro cancer-cell study; inavolisib is a combination-treatment agent, and no pharmacokinetic parameters are reported. |


</details>

---
<sub>Research data extracted by software from published papers; not clinically validated and not for dosing decisions.</sub>  
<sub>Generated by `docs.py` (scholarv2, release v26.09)</sub>
